Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma
Authors:
- Yan XinYXYan Xin
- Jian-Jun ZhangJZJian-Jun Zhang
- Jin ZhouJZJin Zhou
Open Access
- 1 January 2008
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 14 (32) , 5000-5007
Abstract
AIM: To investigate the aberrant methylation of CHFR promoter in human gastric cancer (GC) and its impact on the expression of CHFR mRNA and protein, as well as its correlation with clinical and histological features of human GC. METHODS: Methylation-specific polymerase chain reaction (MSPCR) was used to detect the methylation status of CHFR promoter in 20 primary GC samples and paired normal gastric mucosa. The CHFR mRNA and protein expressions were investigated both by RT-PCR and by Western blotting. The CHFR protein expression in 69 GC samples was immunohistochemically examined. RESULTS: The DNA methylation of the CHFR gene was found in 9 of the 20 GC samples (45%) and the down-regulation of CHFR mRNA and protein was significantly associated with the methylation status of the CHFR gene (P = 0.006). In 20 samples of corresponding non-neoplastic mucosa, no DNA methylation of the CHFR gene was detected. The CHFR gene methylation in poorly differentiated GC samples was significantly higher than that in well-differentiated GC samples (P = 0.014). Moreover, the negative CHFR protein expression rate in paraffin-embedded GC samples was 55.07% (38/69), the positive rate in poorly differentiated GC samples was 36.73% (18/49), which was significantly lower than 65.00% (13/20) in well-differentiated GC samples (χ2 = 4.586, P = 0.032). CONCLUSION: Aberrant methylation of the CHFR gene may be involved in the carcinogenesis and development of GC, and is the predominant cause of down-regulation or loss of CHFR mRNA or protein expression. As aberrant methylation of CHFR promoter is correlated with tumor differentiation, it may help to predict the prognosis of GC and CHFR may become a novel target of gene therapy for GC in the future.Keywords
This publication has 35 references indexed in Scilit:
- The involvement of promoter methylation and DNA methyltransferase-1 in the regulation of EpCAM expression in oral squamous cell carcinomaOral Oncology, 2009
- Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancerBiochemical and Biophysical Research Communications, 2008
- Quantitative promoter methylation analysis of hepatocellular carcinoma, cirrhotic and normal liverInternational Journal of Cancer, 2008
- Epigenetics in CancerNew England Journal of Medicine, 2008
- Epigenetics: differential DNA methylation in mammalian somatic tissuesThe FEBS Journal, 2008
- The Role of Pyrosequencing in Head and Neck Cancer EpigeneticsJAMA Otolaryngology–Head & Neck Surgery, 2008
- DNA methylation in hepatocellular carcinomaWorld Journal of Gastroenterology, 2008
- p16 promoter hypermethylation: A useful serum marker for early detection of gastric cancerWorld Journal of Gastroenterology, 2008
- Chfr defines a mitotic stress checkpoint that delays entry into metaphaseNature, 2000
- Epigenetic modification is involved in aberrant expression of class III β-tubulin, TUBB3, in ovarian cancer cellsInternational Journal of Oncology, 1992